Categories: Latest

Blood vessel-forming cells involved in aggressive brain tumour

Targeting cells involved in blood vessel formation could prevent the growth of the most common type of brain tumour.

Selangor, June 22, 2018: A type of highly malignant brain tumour contains a large number of cells involved in the formation of new blood vessels, helping it proliferate and spread. Targeting these cells could hinder tumour growth, according to new research published in the Pertanika Journal of Science & Technology.

Astrocytomas are tumours that can be found in the brain and spinal cord and originate from a type of cell, called an astrocyte, whose main function is to insulate and to provide structure for nerve fibres. They are the most common type of tumour that originates in the brain. There are four grades of astrocytomas, ranging from least to most aggressive. Grade IV astrocytomas are highly invasive and are almost always fatal. Lower grade astrocytomas are typically found in younger people while higher grade tumours are more often found in older adults.

Astrocytomas depend on new blood vessel formation to grow and spread. Researchers in Malaysia wanted to know how the numbers of ‘endothelial progenitor cells’ (EPCs), which play a role in new vessel formation, changed with increasing grades of astrocytoma. EPCs represent a variety of cell types that circulate in the blood and adhere to the inner linings of blood vessels.

The team of scientists examined brain tissue from 22 astrocytoma patients at the Hospital of University Sains Malaysia. They found that the numbers of endothelial progenitor cells were higher in the tumours than they were in surrounding healthy tissue. They also found that the numbers of these cells inside tumour tissue increased with age and higher tumour grade.

Previous research has shown that patients with grades III and IV astrocytomas who underwent radiotherapy or chemotherapy demonstrated a reduction in the numbers of circulating EPCs. People with grades III and IV astocytomas who didn’t undergo treatment had higher numbers of circulating EPCs than healthy people.

Other studies have also shown that significantly reducing EPCs led to impaired and delayed growth in tumours followed by a reduction in the numbers of blood vessels feeding them.

The researchers conclude that their findings suggest that drugs targeting new blood vessel formation given in appropriate doses according to age and tumour grade could prevent astrocytoma growth.

Corporate Comm India(CCI Newswire)

The Pharma Times News Bureau

Recent Posts

8 Ways Insomnia Affects Skin Health & How To Avoid It

By Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru Insomnia, the persistent inability…

1 day ago

Breaking New Ground in Migraine Care: A Landmark Session on Diagnosis and Treatment

Illuminating Latest Advances in Migraine Diagnosis and Treatment New Delhi, December 21, 2024: In a…

1 day ago

Healthcare Startups to Watch Out for in 2025

New Delhi, December 20, 2024: The healthcare sector is undergoing a transformation fueled by technological…

2 days ago

DKMS’s First Global Impact Report of 2023 Serves as New Ray of Hope for Blood Cancer Patients Worldwide

National, December 20, 2024: DKMS just published its first Global Impact Report that outlines the organization's…

2 days ago

Sterling Biotech to start world’s first precision fermentation-based dairy protein factory in Gujarat

Ahmedabad, December 19, 2024: Sterling Biotech Limited, a joint venture between Perfect Day and Zydus, has…

3 days ago

Pioneers in Senior Care, Antara, Partners with Leading Diagnostics Player Dr. Lal PathLabs to Strengthen its Geriatric Care Services

New Delhi, December 19, 2024: Antara Senior Care, an integrated eco-system provider for lifestyle and…

3 days ago